Peregrine Announces Issuance of Broad Patent Covering Vascular Targeting Agents in Combination Therapy Regimens

Researchers Report Peregrine's Phospholipid-Targeted Antibodies Fused With Cytokines Reduce Tumor Growth in Animals by Over 90%

Peregrine's Anti-Phospholipid Technology Platform Broadened by Newly Validated Anti-Cancer Target

Peregrine to Initiate Bavituximab Combination Therapy Trial in India With Multiple Cancer Chemotherapy Regimens

Peregrine Pharmaceuticals Reports Financial Results for First Quarter FY 2007

Peregrine Pharmaceuticals to Announce First Quarter FY 2007 Financial Results

Peregrine's Final HCV Phase 1a Study Results Accepted for Oral Presentation at AASLD Annual Meeting

Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2006

Peregrine Pharmaceuticals to Announce Year-End FY 2006 Financial Results

Peregrine Pharmaceuticals to Join Russell 3000(R) Index